Dasatinib is active in imatinib-resistant and imatinib-intolerant patients with CML
This article has no abstract so we have provided the first paragraph of the full text.
Imatinib is widely used in the treatment of chronic myeloid leukemia (CML), a disorder characterized by the presence of the BCR-ABL fusion gene; however, the therapeutic options for patients with imatinib-resistant or imatinib-intolerant chronic-phase CML (CML-CP) are limited. A recent phase II study showed that dasatinib, a novel oral agent active against BCR-ABL, induce remarkable responses in patients with CML-CP resistant or intolerant to imatinib.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.